14 May Clinical Data for Amphivena Therapeutics’ Lead Program to be presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting
SOUTH SAN FRANCISCO, CA – May 14, 2020 — Amphivena Therapeutics, a clinical-stage immuno-oncology company focused on developing immuno-therapeutics that restore anti-cancer immunity to the patient, today announced that the first clinical data from the phase 1 study to evaluate its lead therapeutic candidate, AMV564,...